Br J Clin Pharmacol. 2010 Dec; 70(6):825?three. [PubMed: 21175438] 50. Young A, Anzures-Cabrera J, Derks M. No clinically relevant drug-drug interactions when dalcetrapib is co-administered having a monophasic oral contraceptive (Microgynon(R) 30). Int J Clin Pharmacol Ther. 2012 Apr; 50(4):248?six. [PubMed: 22456295] 51. Baldo PA, Anzures-Cabrera J, Bentley D. In vivo evaluation of drug-drug interactions linked to UGT inhibition: the impact of probenecid on dalcetrapib pharmacokinetics. Int J Clin Pharmacol Ther. 2013 Jan 29. 52. Luscher TF, Taddei S, Kaski JC, et al. Vascular effects and security of dalcetrapib in individuals with or at threat of coronary heart illness: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012 Apr; 33(7):857?five. [PubMed: 22345126] 53. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic illness using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011 Oct 29; 378(9802):1547?9. [PubMed: 21908036] 54. Schwartz GG, Olsson AG, Abt M, et al. Effects of Dalcetrapib in Sufferers with a Current Acute Coronary Syndrome.Formula of 1316219-88-1 N Engl J Med.Formula of 2-Methylpyrimidine 2012 Nov 5. 55. Krishna R, Garg A, Panebianco D, et al. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2009 Oct; 68(4):535?five. [PubMed: 19843057] 56. Krishna R, Bergman AJ, Jin B, et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in wholesome subjects. Clin Pharmacol Ther. 2008 Dec; 84(6):679?3. [PubMed: 18580870] 57. Tan EY, Hartmann G, Chen Q, et al. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor in the cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metab Dispos. 2010 Mar; 38(three):459?3. [PubMed: 20016052] 58. Kumar S, Tan EY, Hartmann G, et al. Metabolism and excretion of anacetrapib, a novel inhibitor on the cholesteryl ester transfer protein, in humans.PMID:24324376 Drug Metab Dispos. 2010 Mar; 38(three):474?three. [PubMed: 20016053] 59. Krishna R, Garg A, Jin B, et al. Assessment of a pharmacokinetic and pharmacodynamic interaction involving simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in wholesome subjects. Br J Clin Pharmacol. 2009 Might; 67(5):520?. [PubMed: 19552746] 60. Krishna R, Stypinski D, Ali M, et al. Lack of an impact of anacetrapib around the pharmacokinetics of digoxin in healthy subjects. Biopharm Drug Dispos. 2011 Dec; 32(9):525?. [PubMed: 22031172] 61. Krishna R, Stypinski D, Ali M, et al. Lack of a meaningful effect of anacetrapib around the pharmacokinetics and pharmacodynamics of warfarin in healthier subjects. Br J Clin Pharmacol. 2012 Jul; 74(1):116?4. [PubMed: 22243494] 62. Krishna R, Bergman AJ, Jin B, et al. Assessment of the CYP3A-mediated drug interaction possible of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers. J Clin Pharmacol. 2009 Jan; 49(1):80?. [PubMed: 19004846] 63. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux possible and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 2010 Jul; 30(7):1430?. [PubMed: 20448206] 64. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at higher threat for coronary heart illness. N Engl J Med. 2010 Dec 16; 363.